News >

JCAR015 Experience Informs Future CAR-T Studies

Silas Inman @silasinman
Published: Friday, Nov 10, 2017

Mark J. Gilbert, MD

Mark J. Gilbert, MD
The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin (IL)-15 levels, a finding that could help inform future CAR T-cell usage, according to a presentation at the 32nd Annual SITC Meeting.1

Although not directly associated with the rates of cerebral edema, the CD28 costimulatory domain used for the JCAR015 construct has been associated with faster T-cell expansion compared with the 4-1BB costimulatory domain, noted Gilbert.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication
x